Australia markets open in 2 hours 17 minutes

Genetic Technologies Limited (GTG.XA)

CXA - CXA Real-time price. Currency in AUD
Add to watchlist
0.0030-0.0005 (-14.29%)
At close: 03:58PM AEST
Full screen
Previous close0.0035
Open0.0035
Bid0.0030 x N/A
Ask0.0040 x N/A
Day's range0.0035 - 0.0035
52-week range0.0035 - 0.0035
Volume1,510,146
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)1.25
PE ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Acquisition of global direct to consumer ecommerce business

    MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA. Acquisition Highlights Strategic acquisition continues to strengthen the direct-to-consumer channel for GENE.Provides an additional platfor

  • GlobeNewswire

    Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

    MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022. Key Highlights Year to date growth in revenue of 475%Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product salesGeneType Multi-Risk Test re

  • GlobeNewswire

    US Patent Office Grants Patent for COVID-19 Risk Test

    MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection. The granted US patent covers the proprietary technology incorporated into GENE’s geneType COVID-19 Risk Test, which provides a probability